DOI: 10.36347/sjams.2019.v07i10.002

Pages: 3231-3235

Homocysteine is metabolized in the body to convert to cysteine, oxidation of cysteine in vitro is known to be involved in atherogenesis and thrombogenesis. Cysteine is also known to decrease nitric oxide production by endothelial cells and impair endothelial functions. The present study aimed to evaluate the serum homocysteine levels in patients with established coronary artery disease Methods: This prospective cross-sectional study was conducted in the Department of General Medicine and Cardiology, Govt. Medical College and Hospital, Nalgonda. A total of n=21 male and n=16 were selected based on the angiogram evaluation of coronary artery disease they were designated as Group I (Test) group. Similar numbers of the patients in both sexes were selected who did not show any signs of CAD on angiogram they were designated as group II (controls). Serum homocysteine levels were measured with (ELISA) method. Results the angiogram profile of the patients in the test group and found that a maximum number of patients n=19 (51.35%) had a single-vessel disease. The mean serum homocysteine levels in patients with triple vessel disease were found to be maximum both in male and the females similarly the values were found to be increasing from the minor coronary artery disease to triple vessel. The mean serum levels of homocysteine in group II males was 13.56 ± 3.34 µmol/L and female was 14.5 ± 2.53 µmol/L which were significantly lower than the Test male and females mean values of 22.76 ± 1.65 and 21.41 ± 1.23 µmol/L respectively the p values were found to be significant. Conclusion: that elevated serum homocysteine is associated with severity of coronary artery disease. Hence the levels of homocysteine may be the strongest modifiable risk factor for overall morbidity and mortality due to cardiovascular disease. We recommend that the levels of serum homocysteine must be evaluated in all the patients with coronary artery disease.